In the News

For media inquiries, please contact


Centerline Biomedical Announces Successful Structural Heart Animal Study

Centerline Biomedical, Inc. (Centerline) announced Thursday the completion of the second in a series of structural heart navigation animal studies. Physicians from Cleveland Clinic's top-ranked Heart, Vascular and Thoracic Institute evaluated the feasibility of applying the company's augmented reality image guidance technology to navigate structures in a beating heart. Structural heart disease is a multi-billion-dollar market and one of the fastest growing segments within healthcare.


Centerline Biomedical Launches Research and Development Collaboration with Air Force

Centerline Biomedical, Inc. (Centerline) announced Thursday that the Cleveland-based startup company has launched work on a contract to apply its IOPS™ technology platform to service the needs of its collaborators at the 59th Medical Wing (59 MDW), the Air Force's premier healthcare, medical education and research, and readiness wing, located at Joint Base San Antonio-Lackland.


Cleveland Diagnostics Announces Inclusion of IsoPSA® in National Comprehensive Cancer Network® Guidelines for Prostate Cancer Early Detection

CLEVELAND--()--Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection (version 1.2022). The NCCN panel now recommends the use of IsoPSA as an option to further define the probability of high-grade prostate cancer (Gleason score ≥ 3+4, Grade Group 2 or higher) prior to a first biopsy or after a negative biopsy.


XII Medical Completes $30 Million Series A Financing

Cleveland Clinic start-up XII Medical completed a $30 million round of financing. 


New generation of cancer-preventing vaccines could wipe out tumors before they form

When Dave Dubin learned at age 29 that he had colon cancer, it wasnt a big surprise. His grandfather and father had both survived the disease. “It was almost the Dubin way, and we just went on,” Dubin says. He had surgery and chemotherapy, but his cancer came back 10 years later. Genetic testing finally found an explanation for his family’s trials: a mutation in a DNA repair gene that lets genetic errors pile up in dividing cells. 


Cleveland Diagnostics Announces Publication of Real-World Study Demonstrating the Clinical Utility of IsoPSA® for Prostate Cancer Risk Assessment

CLEVELAND--()--Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today the publication of a large real-world clinical utility study in Urology Practice, a peer-reviewed journal of the American Urological Association. The study, led by Dr. Eric Klein, Emeritus Professor and Chair of the Glickman Urological & Kidney Institute at Cleveland Clinic and Cleveland Clinic Lerner College of Medicine, found that the use of IsoPSA led to significant provider behavior modification and a 55 percent net reduction in prostate biopsy recommendations.


Cleveland Clinic Unveils Top 10 Medical Innovations for 2022

Next generation mRNA vaccines. A new PSMA-targeted approach for prostate cancer. A novel treatment for reducing LDL cholesterol. These are some of the innovations that will optimize and change healthcare in the coming year, according to an expert panel of clinicians and researchers. Cleveland Clinic has announced the Top 10 Medical Innovations for 2022. The list of breakthrough technologies was selected by a committee of Cleveland Clinic subject matter experts, led by D. Geoffrey Vince, Ph.D., executive director of Innovations and chair of Biomedical Engineering at Cleveland Clinic.


Launch of Cleveland Clinic Brain Study Marks Unprecedented Effort to Disrupt Neurological Diseases

Cleveland Clinic has launched a landmark study to better understand the mechanisms of neurological diseases, with the goal of pinpointing disease biomarkers early, well before clinical symptoms manifest. The new Cleveland Clinic Brain Study — the largest clinical study ever for brain disease — will prospectively collect data from up to 200,000 neurologically healthy individuals over a 20-year period to identify brain disease biomarkers and targets for preventing and curing neurological disorders.


5 Innovations That Are Changing the Delivery of Care

Experts at Cleveland Clinic have invested in research and technology designed to improve outcomes and the patient experience. From diagnosis and biopsy to surgical approaches and longer-term management—learn more about how the team is leading the way in prostate cancer.


First U.S. Patient Enrolled in Cardionomic's CPNS Pilot Study

Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial U.S. enrollment in their global Cardiac Pulmonary Nerve Stimulation (CPNS) Pilot Study (NCT04814134). The study is evaluating the safety and performance of the CPNS System in patients suffering from acute decompensated heart failure (ADHF), defined as new or worsening symptoms of heart failure. The first U.S. patient was enrolled and implanted at The Ohio State University Wexner Medical Center in Columbus, OH by Principal Investigator, Dr. Sitaramesh Emani, assisted by Dr. Rami Kahwash

   <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >   

Get In Touch With Us